8-K: Matinas BioPharma Appoints Evelyn D'An as New Director and Audit Committee Chair

Matinas BioPharma Holdings, Inc. appoints Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective February 5, 2025.

Summary

• Matinas BioPharma Holdings, Inc. has appointed Evelyn D'An to its Board of Directors, effective February 5, 2025.
• Ms. D'An will serve as an independent director and Chair of the Audit Committee.
• She will also be a member of the Nominating and Corporate Governance Committee.
• The Board has determined that Ms. D'An meets the independence requirements of the NYSE American LLC and the SEC, and qualifies as an audit committee financial expert.
• Ms. D'An has extensive experience in corporate governance, financial oversight, and accounting, having served on corporate boards since 2006 and as a partner at Ernst & Young for 18 years.
• She currently serves on the boards of Zoomcar Holdings, Inc., GHD Group Pty Ltd., and Backblaze, Inc.
• Ms. D'An will be compensated according to the company's standard non-employee director compensation plan.

Sentiment

Score: 7

Explanation: The announcement is positive due to the appointment of an experienced director and audit committee chair, which strengthens the company's corporate governance. However, the inclusion of forward-looking statements and the mention of potential wind-down scenarios introduce some uncertainty.

Positives

• The appointment of Evelyn D'An brings extensive corporate governance and financial oversight experience to Matinas BioPharma's board.
• Ms. D'An's experience as an Audit Committee chair and business leader fills a need for the company.
• Her commercial and strategic expertise complements the experience of the other board members.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties, including those related to the sale of MAT 2203 and the evaluation of other alternatives for the Company, including a winddown or dissolution of the Company.
• The company's product candidates are all in a development stage and are not available for sale or use.

Future Outlook

The company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.

Management Comments

• Jerome D. Jabbour, Chief Executive Officer of Matinas, commented that Evelyn's background as an experienced Audit Committee chair and business leader fills a need, and her commercial and strategic expertise complements the experience of the other Board members.
• He stated that they are honored that she has chosen to join them at this important time for the Company.

Industry Context

The appointment of an experienced financial leader to the board and audit committee is a common practice for publicly traded biopharmaceutical companies to ensure strong corporate governance and financial oversight.

Comparison to Industry Standards

• The appointment of an independent director with financial expertise is in line with corporate governance best practices observed in comparable companies.
• For example, companies like Amgen and Gilead Sciences also maintain audit committees composed of independent directors with financial expertise.
• Evelyn D'An's experience at Ernst & Young and her service on other public company boards positions her well to meet the heightened standards of independence for compensation and audit committee membership.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced director and audit committee chair as a positive development, enhancing corporate governance and financial oversight.
• Employees may benefit from improved corporate governance and strategic direction.
• Customers and suppliers may see the appointment as a sign of stability and commitment to best practices.

Key Dates

Keywords

Board of Directors, Audit Committee, Evelyn D'An, Corporate Governance, Financial Oversight, Matinas BioPharma